<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7073332\results\search\drugs\results.xml">
  <result pre="cell lines. We further identify three potential drug combinations (e.g.," exact="sirolimus" post="plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin)"/>
  <result pre="further identify three potential drug combinations (e.g., sirolimus plus dactinomycin," exact="mercaptopurine" post="plus melatonin, and toremifene plus emodin) captured by the"/>
  <result pre="drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and" exact="toremifene" post="plus emodin) captured by the &quot;Complementary Exposure�? pattern: the"/>
  <result pre="specific drug. Mesalazine (an approved drug for inflammatory bowel disease)," exact="sirolimus" post="(an approved immunosuppressive drug), and equilin (an approved agonist"/>
  <result pre="symptoms) achieved the highest GSEA scores of 3, followed by" exact="paroxetine" post="and melatonin with GSEA scores of 2. We next"/>
  <result pre="the highest GSEA scores of 3, followed by paroxetine and" exact="melatonin" post="with GSEA scores of 2. We next selected 16"/>
  <result pre="drugs. b–e Inferred mechanism-of-action networks for four selected drugs: b" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator), c irbesartan (an angiotensin"/>
  <result pre="selected drugs: b toremifene (first-generation nonsteroidal-selective estrogen receptor modulator), c" exact="irbesartan" post="(an angiotensin receptor blocker), d mercaptopurine (an antimetabolite antineoplastic"/>
  <result pre="estrogen receptor modulator), c irbesartan (an angiotensin receptor blocker), d" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties), and e"/>
  <result pre="mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties), and e" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)."/>
  <result pre="established cell lines17,38. Compared to the classical ESR1-related antiviral pathway," exact="toremifene" post="prevents fusion between the viral and endosomal membrane by"/>
  <result pre="and eventually inhibiting viral replication39. As shown in Fig. 5b," exact="toremifene" post="potentially affects several key host proteins associated with HCoV,"/>
  <result pre="and human immunodeficiency virus (ZEBOV-GP/HIV)18. Altogether, network-predicted SERMs (such as" exact="toremifene" post="and equilin) offer candidate repurposable drugs for 2019-nCoV/SARS-CoV-2. Angiotensin"/>
  <result pre="proteins in the human interactome. As shown in Fig. 5c," exact="irbesartan" post="targets SLC10A1, encoding the sodium/bile acid cotransporter (NTCP) protein"/>
  <result pre="release effectively50. Indeed, the latest study revealed the clinical application:" exact="sirolimus" post="reduced MERS-CoV infection by over 60%51. Moreover, sirolimus usage"/>
  <result pre="clinical application: sirolimus reduced MERS-CoV infection by over 60%51. Moreover," exact="sirolimus" post="usage in managing patients with severe H1N1 pneumonia and"/>
  <result pre="roles in viral maturation and antagonism to interferon stimulation53,54. Mechanistically," exact="mercaptopurine" post="potentially target several host proteins in HCoVs, such as"/>
  <result pre="play essential roles in viral infections56,57. As a biogenic amine," exact="melatonin" post="(N-acetyl-5-methoxytryptamine) (Z = –1.72 and GSEA score = 2) plays a key role"/>
  <result pre="on the function of multiple organs60. The antioxidant effect of" exact="melatonin" post="makes it a putative candidate drug to relieve patients’"/>
  <result pre="to relieve patients’ clinical symptoms in antiviral treatment, even though" exact="melatonin" post="cannot eradicate or even curb the viral replication or"/>
  <result pre="the viral replication or transcription61,62. In addition, the application of" exact="melatonin" post="may prolong patients’ survival time, which may provide a"/>
  <result pre="and eventually eradicate the virus. As shown in Fig. 5e," exact="melatonin" post="indirectly targets several HCoV cellular targets, including ACE2, BCL2L1,"/>
  <result pre="effect as melatonin. By inhibiting mast-cell-derived proteinases and suppressing fibrosis," exact="eplerenone" post="can improve survival of mice infected with encephalomyocarditis virus63."/>
  <result pre="Inferred mechanism-of-action networks for three selected pairwise drug combinations: b" exact="sirolimus" post="(a potent immunosuppressant with both antifungal and antineoplastic properties)"/>
  <result pre="(a potent immunosuppressant with both antifungal and antineoplastic properties) plus" exact="dactinomycin" post="(an RNA synthesis inhibitor for treatment of various tumors),"/>
  <result pre="(an RNA synthesis inhibitor for treatment of various tumors), c" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator) plus emodin (an experimental"/>
  <result pre="experimental drug for the treatment of polycystic kidney), and d" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)"/>
  <result pre="(a biogenic amine for treating circadian rhythm sleep disorders) plus" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties). Sirolimus plus"/>
  <result pre="treatment of various cancer types. An early study showed that" exact="dactinomycin" post="(1 μg/ml) inhibited the growth of feline enteric CoV67. As"/>
  <result pre="As shown in Fig. 6b, our network analysis shows that" exact="sirolimus" post="and dactinomycin synergistically target HCoV-associated host protein subnetwork by"/>
  <result pre="in Fig. 6b, our network analysis shows that sirolimus and" exact="dactinomycin" post="synergistically target HCoV-associated host protein subnetwork by &quot;Complementary Exposure�?"/>
  <result pre="pattern, offering potential combination regimens for treatment of HCoV. Specifically," exact="sirolimus" post="and dactinomycin may inhibit both mTOR signaling and RNA"/>
  <result pre="potential combination regimens for treatment of HCoV. Specifically, sirolimus and" exact="dactinomycin" post="may inhibit both mTOR signaling and RNA synthesis pathway"/>
  <result pre="the Ebola virus glycoprotein39. In vitro assays have demonstrated that" exact="toremifene" post="inhibited growth of MERS-CoV17,69 and SARA-CoV38 (Table 1). Emodin,"/>
  <result pre="Altogether, network analyses and published experimental data suggested that combining" exact="toremifene" post="and emdoin offered a potential therapeutic approach for 2019-nCoV/SARS-CoV-2"/>
  <result pre="plus Melatonin As shown in Fig. 5a, targets of both" exact="mercaptopurine" post="and melatonin showed strong network proximity with HCoV-associated host"/>
  <result pre="As shown in Fig. 5a, targets of both mercaptopurine and" exact="melatonin" post="showed strong network proximity with HCoV-associated host proteins in"/>
  <result pre="interactome network. Recent in vitro and in vivo studies identified" exact="mercaptopurine" post="as a selective inhibitor of both SARS-CoV and MERS-CoV"/>
  <result pre="in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically," exact="melatonin" post="was reported to inhibit calmodulin and calmodulin interacts with"/>
  <result pre="in HCoV infectious bronchitis virus74. As shown in Fig. 6d," exact="mercaptopurine" post="and melatonin may synergistically block c-Jun signaling by targeting"/>
  <result pre="infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and" exact="melatonin" post="may synergistically block c-Jun signaling by targeting multiple cellular"/>
  <result pre="signaling by targeting multiple cellular targets. In summary, combination of" exact="mercaptopurine" post="and melatonin may offer a potential combination therapy for"/>
  <result pre="targeting multiple cellular targets. In summary, combination of mercaptopurine and" exact="melatonin" post="may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by"/>
  <result pre="(Fig. 6d). However, further experimental observations on ACE2 pathways by" exact="melatonin" post="in 2019-nCoV/SARS-CoV-2 are highly warranted. Discussion In this study,"/>
  <result pre="studies showed the potential pulmonary toxicities (including pneumonia) associated with" exact="mesalazine" post="usage81,82. Integration of lung-specific gene expression23 of 2019-nCoV/SARS-CoV-2 host"/>
  <result pre="Ebola virus infectionSci. Transl. Med.20135190ra17910.1126/scitranslmed.3005471 19.HeSet al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
  <result pre="Top. Med. Chem.200441433145410.2174/156802604338781815379656 43.SekoYEffect of the angiotensin II receptor blocker" exact="olmesartan" post="on the development of murine acute myocarditis caused by"/>
  <result pre="Na(+)-dependent taurocholate cotransporting polypeptide activityAntivir. Res.201512014014610.1016/j.antiviral.2015.06.00726086883 46.KoCet al.The FDA-approved drug" exact="irbesartan" post="inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate"/>
  <result pre="deubiquitinating and deISGylating enzymeAntivir. Chem. Chemother.20091915115610.1177/09563202090190040219374142 54.ChengKWet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
  <result pre="Metab. Immune Drug Discov.20126303910.2174/18722141279901531722264213 60.TanDXKorkmazAReiterRJManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatmentJ. Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives:"/>
  <result pre="Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives: a never-ending interaction of" exact="melatonin" post="with reactive oxygen and nitrogen species?J. Pineal Res.200742284210.1111/j.1600-079X.2006.00407.x17198536 62.GalanoATanDXReiterRJOn"/>
  <result pre="melatonin’s metabolites, AFMK and AMKJ. Pineal Res.20135424525710.1111/jpi.1201022998574 63.XiaoJShimadaMLiuWHuDMatsumoriAAnti-inflammatory effects of" exact="eplerenone" post="on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and chloroquine"/>
  <result pre="of eplerenone on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="Gen. Virol.1992733285328810.1099/0022-1317-73-12-32851335030 68.ZhouWBDingQChenLLiuXAWangSToremifene is an effective and safe alternative to" exact="tamoxifen" post="in adjuvant endocrine therapy for breast cancer: results of"/>
  <result pre="its ectodomainFEBS Lett.200858238539010.1016/j.febslet.2007.11.08518070603 73.DaiJInschoEWYuanLHillSMModulation of intracellular calcium and calmodulin by" exact="melatonin" post="in MCF-7 human breast cancer cellsJ. Pineal Res.20023211211910.1034/j.1600-079x.2002.1844.x12071468 74.FungTSLiuDXActivation"/>
  <result pre="Viruses10, 55 (2018). 81.KimJHet al.Acute eosinophilic pneumonia related to a" exact="mesalazine" post="suppositoryAsia Pac. Allergy2013313613910.5415/apallergy.2013.3.2.13623667838 82.GuptaAGulatiSMesalamine induced eosinophilic pneumoniaRespir. Med. Case"/>
 </snippets>
</snippetsTree>
